Under construction – not a live service
Sign in
Taking people in SingaporeNo phase

Studies heart failure patients in Singapore who receive cardiac resynchronization therapy

Follows adults with heart failure who receive a resynchronization device over time.

Plain-language title generated from the registry record
Registry title: Prospective Evaluation of Asians With CRT for Heart Failure

Key facts

Where
Singapore, SingaporeSee the site

Where in Singapore

  • National University HospitalSingapore, SingaporeTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
National University Heart Centre, Singapore
Trial code
NCT02814942
Record updated
9 March 2021
Original description
Aim:To determine the baseline characteristics of heart failure patients in Singapore undergoing cardiac resynchronization therapy (CRT); the long term outcome and predictors of response to CRT.Read full original descriptionShow less

Prospective Evaluation of Asians With CRT for Heart Failure

Aim:To determine the baseline characteristics of heart failure patients in Singapore undergoing cardiac resynchronization therapy (CRT); the long term outcome and predictors of response to CRT.

Methodology:Among patients undergoing CRT for severe heart failure according to indications stipulated in international Cardiology guidelines, baseline demographic data is collected. Age, gender, NYHA functional class, co-morbidities, QRS width on ECG, presence of left bundle branch block pattern on ECG, presence of atrial fibrillation, left ventricular ejection fraction (LVEF) on echocardiogram, ventricular dimensions, 6 min walk test distance are collected. In addition, during the CRT implant procedure, blood is drawn from the vascular access and analysed for NT-pro BNP levels and other biomarkers of heart failure.

The echocardiographic and ECG parameters and blood biomarkers are reanalysed at 6 months and 12 months following CRT implant. Response to CRT is defined as a reduction in the iLVESV (left ventricular end-systolic volume index to body surface area) of >/= 15% and/or an increase in the LVEF of >/= 10%.

Inclusion: Broad QRS (>120 ms); EF < 40%; Symptomatic heart failure; Not on optimal medical therapy.

Exclusion: Infection; < 18 years of age; Pregnant; Unable to consent.

ClinicalTrials.gov NCT02814942